219 related articles for article (PubMed ID: 35600592)
1. A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome.
Merz LM; Buerger F; Ziegelasch N; Zenker M; Wieland I; Lipek T; Wallborn T; Terliesner N; Prenzel F; Siekmeyer M; Dittrich K
Front Endocrinol (Lausanne); 2022; 13():866831. PubMed ID: 35600592
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
3. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
4. Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report.
Khadora M; Mughal MZ
Bone Rep; 2021 Dec; 15():101138. PubMed ID: 34660853
[TBL] [Abstract][Full Text] [Related]
5. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
6. Approach to Hypophosphatemic Rickets.
Ackah SA; Imel EA
J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
[TBL] [Abstract][Full Text] [Related]
7. A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets.
Huynh C; Gillis A; Fazendin J; Abdullatif H
Bone Rep; 2022 Dec; 17():101605. PubMed ID: 35899095
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
Lim YH; Ovejero D; Derrick KM; ; Collins MT; Choate KA
J Am Acad Dermatol; 2016 Aug; 75(2):420-7. PubMed ID: 27444071
[TBL] [Abstract][Full Text] [Related]
9. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
[TBL] [Abstract][Full Text] [Related]
10. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
[TBL] [Abstract][Full Text] [Related]
11. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
12. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
[TBL] [Abstract][Full Text] [Related]
13. Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome.
Abebe L; Phung K; Robinson ME; Waldner R; Carsen S; Smit K; Tice A; Lazier J; Armour C; Page M; Dover S; Rauch F; Koujok K; Ward LM
Bone Rep; 2024 Mar; 20():101725. PubMed ID: 38229908
[TBL] [Abstract][Full Text] [Related]
14. Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).
Bai X; Levental M; Karaplis AC
J Clin Endocrinol Metab; 2022 Sep; 107(10):2777-2783. PubMed ID: 35896139
[TBL] [Abstract][Full Text] [Related]
15. Successful Burosumab Treatment in an Adult Patient with X-Linked Hypophosphatemia and Chronic Kidney Disease Stage 3b.
Michon-Colin A; Bouderlique E; Prié D; Maruani G; Nevoux J; Briot K; Courbebaisse M
Calcif Tissue Int; 2024 Mar; 114(3):310-314. PubMed ID: 38195892
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
17. Burosumab treatment for fibrous dysplasia.
Gladding A; Szymczuk V; Auble BA; Boyce AM
Bone; 2021 Sep; 150():116004. PubMed ID: 33984553
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.
Ovejero D; Lim YH; Boyce AM; Gafni RI; McCarthy E; Nguyen TA; Eichenfield LF; DeKlotz CM; Guthrie LC; Tosi LL; Thornton PS; Choate KA; Collins MT
Osteoporos Int; 2016 Dec; 27(12):3615-3626. PubMed ID: 27497815
[TBL] [Abstract][Full Text] [Related]
19. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
[TBL] [Abstract][Full Text] [Related]
20. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
Takashi Y; Kawanami D; Fukumoto S
Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]